| __timestamp | BeiGene, Ltd. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21862000 | 79696000 |
| Thursday, January 1, 2015 | 58250000000 | 93236000 |
| Friday, January 1, 2016 | 98033000 | 150842000 |
| Sunday, January 1, 2017 | 269018000 | 150643000 |
| Monday, January 1, 2018 | 679005000 | 150252000 |
| Tuesday, January 1, 2019 | 927338000 | 140804000 |
| Wednesday, January 1, 2020 | 1294877000 | 34236000 |
| Friday, January 1, 2021 | 1459239000 | 35672000 |
| Saturday, January 1, 2022 | 1640508000 | 66607000 |
| Sunday, January 1, 2023 | 1778594000 | 76363000 |
| Monday, January 1, 2024 | 79048000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. BeiGene, Ltd. and Halozyme Therapeutics, Inc. offer a fascinating contrast in their R&D investment strategies over the past decade.
From 2014 to 2023, BeiGene's R&D expenses skyrocketed by over 8,000%, reflecting its aggressive pursuit of new therapies. In 2015 alone, BeiGene's R&D spending surged to nearly 50 times its 2014 level, underscoring its rapid expansion. By 2023, BeiGene's R&D investment reached approximately $1.8 billion, a testament to its sustained growth.
Conversely, Halozyme's R&D spending remained relatively stable, peaking in 2016 and then gradually declining. This steady approach suggests a more conservative strategy, focusing on optimizing existing technologies. As of 2023, Halozyme's R&D expenses were about 4% of BeiGene's, highlighting the stark difference in their investment philosophies.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and BeiGene, Ltd.
Research and Development Investment: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
BeiGene, Ltd. vs Incyte Corporation: Strategic Focus on R&D Spending
R&D Spending Showdown: BeiGene, Ltd. vs MorphoSys AG
R&D Insights: How BeiGene, Ltd. and MannKind Corporation Allocate Funds
BeiGene, Ltd. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Halozyme Therapeutics, Inc.
Research and Development Investment: Jazz Pharmaceuticals plc vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and MorphoSys AG
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Viridian Therapeutics, Inc.